NBL

NBL Biotech, a wholly-owned subsidiary of CSPC Pharmaceutical Group, is a clinical-stage biotechnology company specializing in the discovery and development of innovative antibody therapeutics. The company focuses on high-potential targets in oncology and autoimmune diseases, utilizing its proprietary antibody discovery and engineering platforms. Its clinical pipeline includes NBL-012, an IL-23p19 monoclonal antibody in Phase 2 trials for psoriasis, and NBL-015, a Claudin 18.2-targeting antibody for gastric and pancreatic cancers. NBL Biotech maintains a global presence with research and clinical operations in both Nanjing, China, and Princeton, New Jersey. By integrating advanced biologics R&D with the commercial scale of its parent company, NBL aims to deliver next-generation treatments for patients worldwide.